Daxotel 120 mg Injection
Brand Name: Daxotel
Molecule: Docetaxel
Strength: 120 mg
Quantity: 1 Vial
Form: Injection
Packaging Type: Vial
Manufacturer/Marketed By: Fresenius Kabi
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
No similar products found.
Description
Daxotel injection are manufactured by Wockhardt in India and contain Varies of Docetaxel per injection. Each Vial includes Single vial, making Daxotel injection an effective option for Chemotherapy . Prescription Required from your healthcare provider to purchase Docetaxel medicine. Indogenmed deals in all type of generic Dexamethasone medicine.
Benefits
-
A taxane chemotherapy agent widely used in oncology
-
Interferes with cancer cell division, slowing tumor growth
-
Can be used alone or in combination with other chemotherapy medicines
-
Part of established chemotherapy protocols for multiple cancers
-
Administered under medical supervision in specialized oncology settings
Indications and Usage
Daxotel (docetaxel) may be prescribed for:
-
Breast cancer
-
Non-small cell lung cancer (NSCLC)
-
Metastatic prostate cancer
-
Gastric (stomach) cancer
-
Head and neck cancers
-
Other oncology indications where docetaxel-based chemotherapy is recommended by an oncologist
Treatment selection depends on cancer type, stage, and prior therapies.
How it Works
Docetaxel works by stabilizing microtubules, which are structural components required for cell division. Normally, microtubules assemble and disassemble during the cell cycle to allow chromosomes to separate during mitosis. Docetaxel binds to microtubules and prevents them from breaking down, which disrupts the normal process of cell division.
As a result, cancer cells are unable to divide and multiply effectively, leading to cell death. Because rapidly dividing cancer cells are more sensitive to this mechanism, docetaxel can help slow tumor growth when administered as prescribed and monitored by an oncology specialist.
Dosage & Administration
-
Daxotel is administered as an intravenous infusion in a hospital or oncology clinic.
-
The dosage is calculated based on body surface area and treatment protocol.
-
Infusions are typically given every 3 weeks, depending on the chemotherapy regimen.
-
Premedication such as corticosteroids may be given to reduce the risk of allergic reactions and fluid retention.
-
Treatment duration and cycles are determined by the oncologist based on clinical response and tolerance.
Side Effects
Common side effects
-
Hair loss
-
Fatigue
-
Nausea or vomiting
-
Diarrhea
-
Nail changes
-
Mouth sores (stomatitis)
-
Low blood cell counts
Serious side effects
-
Severe neutropenia (very low white blood cells)
-
Severe infections
-
Fluid retention
-
Allergic or infusion-related reactions
-
Peripheral neuropathy (nerve damage causing numbness or tingling)
-
Liver function abnormalities
Patients should seek medical attention if serious symptoms occur.
Warning and Precaution
-
Risk of severe neutropenia and infection
-
Possible fluid retention and swelling
-
Potential liver function abnormalities
-
Infusion-related or allergic reactions may occur
-
Peripheral neuropathy may develop with prolonged treatment
-
Avoid use during pregnancy unless specifically advised by a doctor
-
Regular blood tests and monitoring are required during therapy
Patient Guidance
-
Treatment should be administered only by trained healthcare professionals
-
Attend all scheduled chemotherapy sessions and follow-up visits
-
Report symptoms such as fever, infection, severe fatigue, or numbness
-
Follow your doctor’s instructions regarding premedications and supportive care
-
Maintain good hydration and nutrition during treatment
-
Do not alter or discontinue treatment without consulting your oncologist
Clinical Trial & Approvals
Docetaxel has been evaluated in numerous clinical trials across various cancers. These studies demonstrated its effectiveness in improving outcomes in cancers such as breast, lung, and prostate cancer when used alone or in combination chemotherapy regimens. Based on these findings, docetaxel has received approvals from regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for multiple oncology indications.
References
-
U.S. Food and Drug Administration (FDA) – Docetaxel Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020449s082lbl.pdf -
European Medicines Agency (EMA) – Docetaxel Product Information
https://www.ema.europa.eu -
National Cancer Institute – Docetaxel Drug Information
https://www.cancer.gov -
Drugs.com – Docetaxel Drug Information
https://www.drugs.com -
ClinicalTrials.gov – Docetaxel Clinical Studies
https://clinicaltrials.gov
Prescription & documentation note
Daxotel 120 mg Injection is typically supplied against a valid prescription and administered in a clinical setting. For international supply requests, patients may need to provide documentation such as a licensed physician’s prescription, medical records, and identification, depending on destination country regulations.
FAQ
What is Daxotel 120 mg Injection used for?
It is used in chemotherapy treatment for cancers such as breast cancer, lung cancer, prostate cancer, gastric cancer, and head and neck cancers.
What is the active ingredient in Daxotel?
The active ingredient is docetaxel, a taxane chemotherapy drug.
How is Daxotel administered?
It is given as an intravenous infusion in a hospital or oncology clinic.
Can Daxotel be used with other cancer medicines?
Yes. It is often used in combination with other chemotherapy agents depending on the treatment plan.
How often is docetaxel treatment given?
Treatment is commonly given every three weeks, though schedules may vary depending on the protocol.
Does docetaxel affect blood cells?
Yes. It may lower blood cell counts, so regular blood tests are required during treatment.
Is Daxotel a prescription medicine?
Yes. It is a prescription-only chemotherapy medicine administered under medical supervision.
How should Daxotel injection be stored?
Storage and handling should follow manufacturer guidelines and hospital pharmacy protocols.
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
READ MORE »May 6, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.